Seres Therapeutics, Inc. (MCRB)
NASDAQ: MCRB · Real-Time Price · USD
15.65
+0.60 (3.96%)
Jan 22, 2026, 1:08 PM EST - Market open
Seres Therapeutics Revenue
Seres Therapeutics had revenue of $351.00K in the quarter ending September 30, 2025.
Revenue (ttm)
$351.00K
Revenue Growth
n/a
P/S Ratio
404.64
Revenue / Employee
$3,408
Employees
103
Market Cap
141.54M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | 144.93M | 111.71M | 336.33% |
| Dec 31, 2020 | 33.22M | -1.29M | -3.74% |
| Dec 31, 2019 | 34.51M | 6.24M | 22.07% |
| Dec 31, 2018 | 28.27M | -3.83M | -11.94% |
| Dec 31, 2017 | 32.10M | 10.33M | 47.48% |
| Dec 31, 2016 | 21.77M | - | - |
| Dec 31, 2015 | - | - | - |
| Dec 31, 2014 | - | - | - |
| Dec 31, 2013 | - | - | - |
| Dec 31, 2012 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Sutro Biopharma | 105.65M |
| Spero Therapeutics | 40.55M |
| Sangamo Therapeutics | 32.88M |
| Whitehawk Therapeutics | 14.38M |
| Caribou Biosciences | 9.30M |
| Fate Therapeutics | 7.14M |
| Oramed Pharmaceuticals | 2.00M |
| Connect Biopharma Holdings | 762.00K |
MCRB News
- 16 days ago - Seres Therapeutics Announces Publications in Nature Medicine and Journal of Infectious Diseases Highlighting Vowst™ Mechanism of Action and Supporting Broader Live Biotherapeutic Strategy - GlobeNewsWire
- 2 months ago - Seres Therapeutics to Participate in Piper Sandler Healthcare Conference - GlobeNewsWire
- 2 months ago - Seres Therapeutics, Inc. (MCRB) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 2 months ago - Seres Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Updates - GlobeNewsWire
- 3 months ago - Seres Therapeutics to Announce Third Quarter 2025 Financial Results and Business Updates on November 5, 2025 - GlobeNewsWire
- 3 months ago - Seres Therapeutics Receives Award of Up to $3.6 Million from CARB-X to Develop Liquid Formulation of SER-155 - GlobeNewsWire
- 3 months ago - Seres Therapeutics to Present New Post Hoc Data From SER-155 Phase 1b Trial at IDWeek 2025, Highlighting Potential to Improve Outcomes in Adults Undergoing Allogeneic Hematopoietic Stem Cell Transplant - GlobeNewsWire
- 4 months ago - Seres Therapeutics Announces Further Constructive Feedback from FDA on SER-155 Phase 2 Study Protocol and Implements Cost Reduction Actions to Extend Cash Runway - GlobeNewsWire